title: Association of laryngopharyngeal manifestations and gastroesophageal reflux.
abstract: The aim of this study was to investigate the prevalence of gastroesophageal reflux disease (GERD) in patients with laryngopharyngeal symptoms, the relationship between laryngopharyngeal reflux (LPR) and Helicobacter Pylori infection and treatment response to proton pump inhibitors. Forty-five patients with suspected gastroesophageal reflux diseases related symptoms (sore throat, throat burning, throat clearing, globus sensation, cough, halitozis, dysphonia, dysphagia, postnasal dripping, vocal fatigue, and sputum) were included in this study. For pre-therapeutic and post-therapeutic comparison, symptoms and laryngological findings were graded on a 4-point scale. The patients underwent upper gastrointestinal system endoscopy. During endoscopy, antral biopsies from the stomach were obtained to detect H. Pylori. Antireflux medication with proton pump inhibitors (PPI) and H. Pylori eradication therapy if present were prescribed to the patients. The improvement in symptoms and laryngological findings were evaluated after treatment. By means of esophagogastroduodenoscopy (EGD), reflux was detected in only 11% of patients. But there can be reflux patients other than the detected ones. Although, H. Pylori was present in 62% of patients, no correlation was found between H. Pylori positivity and symptoms. All patients responded well to antireflux treatment and H. Pylori eradication therapy. Laryngopharyngeal symptoms and findings can be predictors of gastroesophageal diseases when response to reflux treatment is taken into account.
authors.affiliation: Deparment of Otorhinolaryngology/Head and Neck Surgery, Haydarpaşa Numune Educational and Research Hospital, M Saadettin Sokak, Saadet Apartmani, Istanbul, Ortaköy/Beşiktaş, Turkey. semazertoros@yahoo.com
authors.forename: Sema Zer
authors.initials: SZ
authors.lastname: Toros
authors.forename: Ahmet Burak
authors.initials: AB
authors.lastname: Toros
authors.forename: Ozlem Doganer
authors.initials: OD
authors.lastname: Yüksel
authors.forename: Leyla
authors.initials: L
authors.lastname: Ozel
authors.forename: Cinar
authors.initials: C
authors.lastname: Akkaynak
authors.forename: Baris
authors.initials: B
authors.lastname: Naiboglu
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D016145:Endoscopy, Digestive System / Q000379:methods; D004941:Esophagitis / Q000175:diagnosis*; D005260:Female; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000453:epidemiology* / Q000503:physiopathology*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D064747:Lansoprazole; D007830:Larynx / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D010614:Pharynx / Q000503:physiopathology*; D015995:Prevalence; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D064747:Lansoprazole